RT Journal Article
SR Electronic
T1 Latent Hypothyreosis as a Clinical Biomarker for Therapy Response Under Abiraterone Acetate Therapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 307
OP 311
VO 34
IS 1
A1 ISABEL HEIDEGGER
A1 UDO NAGELE
A1 ANDREAS PIRCHER
A1 RENATE PICHLER
A1 WOLFGANG HORNINGER
A1 JASMIN BEKTIC
YR 2014
UL http://ar.iiarjournals.org/content/34/1/307.abstract
AB Background: Abiraterone acetate (AA) is a selective oral inhibitor of Steroid-17α-Hydroxylase, for patients with castration-resistant prostate cancer. Not all patients respond to therapy, however, there are no biomarkers predicting response to AA therapy. The aim of the present study was the identification of a biomarker for patients who are likely to respond to AA therapy. Patients and Methods: We measured thyroid parameters in a collective of 30 patients before and during AA therapy. For statistical analyses, paired and unpaired t-tests were used. Results: During AA therapy, responders developed a significant increase in thyroid stimulating hormone (TSH) compared to non-responders (p=0.03). In the subgroup of responders, 16 out of 21 patients (76.1%) had a significant increase in TSH level (p=0.001), suggesting that TSH increase is predictive of therapy response. Non-responders showed no change in TSH level during AA therapy. Conclusion: Hypothyreosis may serve as a simple predictive biomarker for therapy response under AA therapy.